MARKET

ALRN

ALRN

Aileron
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.090
+0.020
+1.87%
After Hours: 1.080 -0.01 -0.92% 17:42 11/23 EST
OPEN
1.100
PREV CLOSE
1.070
HIGH
1.130
LOW
1.070
VOLUME
688.38K
TURNOVER
--
52 WEEK HIGH
2.470
52 WEEK LOW
0.2500
MARKET CAP
44.35M
P/E (TTM)
-1.4141
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
New Strong Sell Stocks for November 19th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.
Zacks · 4d ago
Aileron Therapeutics EPS in-line
Aileron Therapeutics (ALRN): Q3 GAAP EPS of -$0.13 in-line.Cash, cash equivalents and investments of $14.1M.Press Release
Seekingalpha · 11/13 03:28
Mastercard, Akamai Technologies leads premarket losers' pack
Neovasc (NVCN) -38% as FDA Ad Com thumbs down on Neovasc Reducer.Akerna (KERN) -16%.Six Flags Entertainment (SIX) -11% on Q3 earnings release.Bed Bath & Beyond (BBBY) -10% on announcing buyback activity after selling assets.Big 5 Sporting
Seekingalpha · 10/28 12:44
AIG, HSBC, XLNX and EXAS among premarket gainers
1847 Goedeker (GOED) +81% on announcing agreement for the acquisition of Appliances Connection.SPI Energy (SPI) +40%.Sunworks (SUNW) +17%.Xilinx (XLNX) +13% as AMD to acquire the company in an all-stock transaction valued at $35B.Neptune Wellness
Seekingalpha · 10/27 12:21
Mid-Afternoon Market Update: Crude Oil Down Over 3%; SAP Shares Slide On Lowered Outlook
Toward the end of trading Monday, the Dow traded down 2.74% to 27560.09 while the NASDAQ fell 2.16% to 11,298.61. The S&P also fell, dropping 2.24% to 3,387.72.
Benzinga · 10/26 18:33
SAP, DNKN, CODX and NNDM among midday movers
Gainers: Document Security Systems (DSS) +43%.Muscle Maker (GRIL) +39%.Lianluo Smart (LLIT) +35%.Co-Diagnostics (CODX) +19%.SilverSun Technologies (SSNT) +18%.Mid-Con Energy Partners (MCEP) +18%.Galera Therapeutics (GRTX) +15%.Dunkin' Brands (DNKN) +15%.GeoVax Labs (GOVX) +14%.Selecta Biosciences (SELB) +13%.Losers: BioSig
Seekingalpha · 10/26 16:38
Mid-Day Market Update: Dow Tumbles 650 Points; Lianluo Smart Shares Climb
Midway through trading Monday, the Dow traded down 2.31% to 27680.07 while the NASDAQ fell 1.56% to 11,367.63. The S&P also fell, dropping 1.97% to 3,397.27.
Benzinga · 10/26 16:34
Why Aileron's Stock Is Trading Lower Today
Aileron Therapeutics (NASDAQ: ALRN) shares are trading lower on Monday after the company on Saturday announced clinical data from its ongoing Phase 1b trial of ALRN-6924.
Benzinga · 10/26 14:35
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALRN. Analyze the recent business situations of Aileron through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALRN stock price target is 5.00 with a high estimate of 8.00 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 48
Institutional Holdings: 9.17M
% Owned: 22.54%
Shares Outstanding: 40.68M
TypeInstitutionsShares
Increased
8
264.12K
New
17
-1.16M
Decreased
3
208.72K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.80%
Pharmaceuticals & Medical Research
-0.36%
Key Executives
Chairman/Director
Jeffrey Bailey
President/Chief Executive Officer/Director
Manuel Aivado
Chief Financial Officer/Treasurer/IR Contact Officer
Rick Wanstall
Senior Vice President
D. Allen Annis
Senior Vice President
Vojislav Vukovic
Lead Director/Independent Director
Reinhard Ambros
Independent Director
William McKee
Independent Director
Jodie Morrison
Independent Director
Nolan Sigal
Independent Director
Josef von Rickenbach
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ALRN
Aileron Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation. The Company is advancing its lead oncology program to deliver efficacy and safety in a spectrum of solid and hematological malignancies. Its lead product candidate, ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers. The Company is conducting an ongoing Phase I clinical trial of ALRN-6924 in adult patients with solid tumors or lymphomas expressing non-mutated or wild-type p53 that are refractory to or intolerant of standard therapy. ALRN-6924 may reactivate p53-mediated cell death by targeting both of the natural p53 suppressor proteins, Mouse double minute 2 homolog (MDM2) and MDMX.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Aileron Therapeutics Inc stock information, including NASDAQ:ALRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALRN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALRN stock methods without spending real money on the virtual paper trading platform.